Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 20, 2019
Distillery Therapeutics

MHCII nanoparticles for autoimmune hepatic diseases

BioCentury | Apr 7, 2017
Clinical News

CPI-613 regulatory update

BioCentury | Mar 25, 2017
Product Development

Pivotal meeting

How Cornerstone’s CPI-613 leapfrogged to pivotal trials in AML, pancreatic cancer
BioCentury | Feb 8, 2016
Clinical News

CPI-613: Phase I data

BioCentury | Jan 5, 2015
Clinical News

CPI-613: Phase I started

BioCentury | Nov 3, 2014
Clinical News

CPI-613: Phase I started

BioCentury | Jun 19, 2014
Cover Story

Breaking MYC metabolism

BioCentury | Jun 2, 2014
Clinical News

CPI-613: Phase I data

Items per page:
1 - 10 of 23
Help Center
Username
Request a Demo
Request Training
Ask a Question